Pharmacokinetics, Safety and Tolerability of Oral Semaglutide in Subjects with Renal Impairment-Reference-Cited by-同舟云学术

Pharmacokinetics, Safety and Tolerability of Oral Semaglutide in Subjects with Renal Impairment

Published:2018-04-06 Issue:12 Volume:57 Page:1571-1580
ISSN:0312-5963
Container-title:Clinical Pharmacokinetics
language:en
Short-container-title:Clin Pharmacokinet

Author:

Granhall Charlotte,Søndergaard Flemming L.,Thomsen Mette,Anderson Thomas W.

Funder

Novo Nordisk A/S, Søborg, Denmark

Publisher

Springer Science and Business Media LLC

Subject

Pharmacology (medical),Pharmacology

Link

http://link.springer.com/article/10.1007/s40262-018-0649-2/fulltext.html

Reference34 articles.

1. Davies M, Chatterjee S, Khunti K. The treatment of type 2 diabetes in the presence of renal impairment: what we should know about newer therapies. Clin Pharmacol. 2016;8:61–81.

2. Arnouts P, Bolignano D, Nistor I, et al. Glucose-lowering drugs in patients with chronic kidney disease: a narrative review on pharmacokinetic properties. Nephrol Dial Transpl. 2014;29(7):1284–300.

3. Kapitza C, Nosek L, Jensen L, Hartvig H, Jensen CB, Flint A. Semaglutide, a once-weekly human GLP-1 analog, does not reduce the bioavailability of the combined oral contraceptive, ethinylestradiol/levonorgestrel. J Clin Pharmacol. 2015;55(5):497–504.

4. Lau J, Bloch P, Schäffer L, et al. Discovery of the once-weekly glucagon-like peptide-1 (GLP-1) analogue semaglutide. J Med Chem. 2015;58(18):7370–80.

5. Sorli C, Harashima SI, Tsoukas GM, et al. Efficacy and safety of once-weekly semaglutide monotherapy versus placebo in patients with type 2 diabetes (SUSTAIN 1): a double-blind, randomised, placebo-controlled, parallel-group, multinational, multicentre phase 3a trial. Lancet Diabetes Endocrinol. 2017;5(4):251–60.

Cited by 87 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Efficacy and Safety in a Real-World Study of the New Oral Formulation of Semaglutide in Patients with Chronic Kidney Disease and Type 2 Diabetes Mellitus;Journal of Clinical Medicine;2024-08-30

2. The Use of Semaglutide in Patients With Renal Failure-A Retrospective Cohort Study;Endocrine Practice;2024-07

3. Efficacy and Safety of Oral Semaglutide in the Treatment of Type 2 Diabetes: A Meta‐Analysis;The Journal of Clinical Pharmacology;2024-06-14

4. Clinical Pharmacokinetics of Semaglutide: A Systematic Review;Drug Design, Development and Therapy;2024-06

5. A phase 1, randomized, double‐blind, placebo‐controlled trial investigating the pharmacokinetics, pharmacodynamics, safety and tolerability of oral semaglutide in healthy Chinese subjects;Diabetes, Obesity and Metabolism;2024-05-29